Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06649851 · ClinicalTrials.gov registry record · Phase 2
G-CSF After Chemo-radiation in Patients With Glioblastoma
A Phase 2 study of Glioblastoma (GBM) and MGMT-Methylated Glioblastoma, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06649851 is a Phase 2 study of Glioblastoma (GBM) and MGMT-Methylated Glioblastoma that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 60 participants, below the 78-participant average among 7 other Glioblastoma (GBM) trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06649851, a Phase 2 study of Glioblastoma (GBM) and MGMT-Methylated Glioblastoma, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study involves the study of granulocyte colony stimulating factor (G-CSF) in patients with MGMT-methylated glioblastoma multiforme (GBM) that are undergoing standard chemoradiation. The study aims to evaluate G-CSF's effects on brain health and cognitive function. The name of the study drugs involved in this study are: * G-CSF (also called Filgrastim) * Temozolomide (TMZ), a standard of care chemotherapy drug
Conditions Studied
Interventions
- DRUG Granulocyte Colony Stimulating Factor (G-CSF)
- RADIATION Radiation Therapy + Temozolomide
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-04-02 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06649851
The ClinicalTrials.gov registry entry for NCT06649851 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 7 other Glioblastoma (GBM) trials with a reported enrollment target (23% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glioblastoma (GBM) appearing as the primary indexed condition, and to 2 interventions - of which Granulocyte Colony Stimulating Factor (G-CSF) is the first listed.
NCT06649851 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06649851 about?
NCT06649851 is a clinical study titled "G-CSF After Chemo-radiation in Patients With Glioblastoma". This research study involves the study of granulocyte colony stimulating factor (G-CSF) in patients with MGMT-methylated glioblastoma multiforme (GBM) that are undergoing standard chemoradiation. The study aims to evaluate G-CSF's effects on brain health and cognitive function. The name of the stud...
What is the current status of trial NCT06649851?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-04-02. Estimated completion is 2030-01-31.
What conditions does trial NCT06649851 study?
This clinical trial studies the following conditions: Glioblastoma (GBM), MGMT-Methylated Glioblastoma, Newly Diagnosed Glioblastoma Multiforme.
What interventions are being tested in trial NCT06649851?
The interventions under investigation include: Granulocyte Colony Stimulating Factor (G-CSF) (DRUG), Radiation Therapy + Temozolomide (RADIATION).
Who is sponsoring clinical trial NCT06649851?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06649851 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma (GBM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial
RECRUITING · Phase 2
-
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
RECRUITING · Phase 2
-
A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
RECRUITING · Early Phase 1
-
Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma
RECRUITING · Phase 1
-
FearLess in NeuroOncology
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.